This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $2,234,905.00 in funding to The University of Iowa to support research aimed at understanding the underlying mechanisms responsible for cognitive fluctuations in Lewy body disorders (LBD). The project will use mouse models to evaluate how the accumulation of...
This three-year, $3.4 million Project Grant from the National Institute on Aging will support research into the combinatorial effects of post-translational modifications on alpha-synuclein structure, function, and aggregation. The Trustees of the University of Pennsylvania will investigate how multiple simultaneous modifications to alpha-synuclein impact its interactions with lipid bilayers, self-association kinetics, aggregate structural features, internalization by neurons, and seeded...
This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $791,086 aims to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes, such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The project will leverage data from autopsy-confirmed datasets, in vivo neuroimaging, and clinical assessments to build...
The federal Project Grant award of $2,674,385 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the structure-function relationship of alpha-synuclein protein strains and their impact on the clinical presentation of Lewy body dementia (LBD) and multiple system atrophy (MSA). The research aims to overcome barriers in using transgenic mouse...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $457,875 to the University of Connecticut Health Center to develop and characterize the first LRP10 knockout mouse model. The goal is to examine how loss of the LRP10 gene function contributes to the pathogenesis of Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. The 2-year project, running from May 2025 to April 2027, will investigate neuroinflammation,...
This $3,013,265 federal project grant award from the National Institute of Neurological Disorders and Stroke (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) will fund research to investigate the causal role of particulate matter components on Lewy body dementia (LBD). The 4-year project, running from August 1, 2025 to July 31, 2029, will utilize epidemiological data, statistical methods, and animal studies to identify which particulate matter...
This $2,069,215 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by Case Western Reserve University to investigate the role of the beta-arrestin2-LMBRD2 pathway in the transmission and toxicity of pathological alpha-synuclein, which is a defining hallmark of Lewy body diseases such as Parkinson's disease and dementia with Lewy bodies. The research will utilize cellular and animal models to study the mechanisms by which beta-arrestin2...
MECHANISMS UNDERLYING HETEROGENEITY OF COGNITIVE OUTCOMES IN SYNUCLEINOPATHY - OVERALL ABSTRACT/SUMMARY THE MISSION OF THIS PENN PO1 CENTER ON "MECHANISMS UNDERLYING HETEROGENEITY OF COGNITIVE OUTCOME IN SYNUCLEINOPATHY" IS TO UNDERSTAND WHY THE SAME UNDERLYING CORE PATHOLOGY - INCLUSIONS OF ALPHA-SYNUCLEIN (ASYN) - VARIES SO WIDELY IN THE PACE AND PATTERN OF SPREAD WITHIN THE BRAIN, RESULTING IN DRAMATICALLY DIVERGENT CLINICAL TRAJECTORIES. THE LEWY BODY DISORDERS (LBD) - NAMELY, DEMENTIA WITH LEWY BODIES (DLB), PARKINSON'S DISEASE (PD), AND ALZHEIMER'S DISEASE WITH LEWY BODIES (LBD+AD) - SHARE THE CORE FEATURE OF NEURONAL ASYN INCLUSIONS. HOWEVER, PATIENTS MANIFEST VERY DIFFERENTLY FROM ONE ANOTHER, WITH DIFFERENCES IN COGNITION PLAYING A VITAL ROLE WITH RESPECT TO PATIENT QUALITY OF LIFE AND COST TO THE HEALTHCARE SYSTEM. BECAUSE THE LBD AFFECT SO MANY, WITH NO FDA-APPROVED DISEASE-MODIFYING THERAPIES, THEY CONSTITUTE ONE OF THE MOST IMPORTANT ALZHEIMER'S DISEASE RELATED DEMENTIAS (ADRD) AFFECTING THE WORLD TODAY. THIS PO1 CENTER HYPOTHESIZES THAT SEVERAL KEY FEATURES PLAY FUNDAMENTAL ROLES IN DETERMINING WHETHER A GIVEN LBD INDIVIDUAL MIGHT DEVELOP DEMENTIA FROM THE OUTSET, AFTER A FEW YEARS, AFTER MANY DECADES, OR NOT AT ALL. THESE FEATURES ARE: (1) THE INTERPLAY OF ASYN WITH - AMYLOID PLAQUES AND TAU NEUROFIBRILLARY TANGLES, (2) THE CONFORMATION OF ASYN, (3) HOST GENOMICS AND PROTEOMICS, AND (4) THE LOCUS/ENTRY POINT OF EARLY PATHOLOGY. WE TEST THIS HYPOTHESIS IN FOUR SYNERGISTIC RESEARCH PROJECTS. PROJECT I INVESTIGATES THE ROLE OF CONCOMITANT -AMYLOID AND TAU PATHOLOGY IN GOVERNING PATTERNS OF ASYN SPREAD IN HUMAN POSTMORTEM BRAIN. PROJECT II CHARACTERIZES HUMAN BRAIN-DERIVED ASYN STRAINS WITH CRYO-ET AND CELL BIOLOGICAL TECHNIQUES. PROJECT III LEVERAGES GENOMIC AND BIOMARKER DATA TO DERIVE CANDIDATE MOLECULAR PLAYERS, THEN MANIPULATES THESE GENES/PROTEINS IN NEURONS TO UNDERSTAND THEIR ROLE IN THE UPTAKE OF FIBRILLAR ASYN, DEVELOPMENT OF ASYN PATHOLOGY, AND CELL-TO-CELL TRANSMISSION OF ASYN PATHOLOGY. PROJECT IV EXTENDS OUR INVESTIGATIONS OF HOST FACTORS TO MOUSE MODELS, TESTING THE ROLE OF GENETIC BACKGROUND, ROUTE OF ASYN EXPOSURE, AND TYPE OF ASYN STRAIN IN MODULATING IN VIVO PATHOLOGICAL ASYN SPREAD. ALL FOUR RESEARCH PROJECTS FOCUS ON MECHANISMS, GROUNDED IN HUMAN DATA, AND THEY ARE SUPPORTED BY FOUR CORES THAT (1) SERVE ADMINISTRATIVE FUNCTIONS, (2) RECRUIT CLINICAL PATIENTS, (3) PROVIDE BIOSAMPLE RESOURCES TO RESEARCH PROJECTS AND TO EXTERNAL INVESTIGATORS, AND (4) MANAGE DATA FOR RESEARCH PROJECTS AND SHARING TO EXTERNAL INVESTIGATORS. THUS, THE PENN PO1 CENTER SEEKS TO DISCOVER AND DEVELOP NEW THERAPEUTIC STRATEGIES TO DELAY OR PREVENT DEMENTIA IN THE LBD.